Targeting a specific pathway in uveal melanoma treatment
Targeting Gq pathway in uveal melanoma
This study is looking at a common type of eye cancer called uveal melanoma, which can spread to the liver, and aims to find new ways to stop the cancer from growing and spreading by targeting a specific pathway in the cells, using advanced techniques to help improve treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10916279 on NIH RePORTER |
What this research studies
This research focuses on uveal melanoma, the most common type of eye cancer, which often leads to severe outcomes due to its tendency to spread to the liver. The study aims to explore the Gq signaling pathway, which is frequently mutated in uveal melanoma, to develop new therapeutic strategies. By utilizing advanced techniques like CRISPR, the researchers will investigate how to effectively inhibit this pathway to prevent cancer cell growth and metastasis. The goal is to identify novel treatments that could improve survival rates for patients suffering from this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with uveal melanoma, particularly those with advanced disease or metastasis.
Not a fit: Patients with other types of melanoma that do not involve the Gq pathway mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for uveal melanoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While targeting the Gq pathway in uveal melanoma is a novel approach, similar strategies in other melanoma types have shown promise, indicating potential for success.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Chen, Xu — University of California, San Francisco
- Study coordinator: Chen, Xu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.